Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease

Movement Disorders Clinical Practice(2025)10.1002/mdc3.70367Source: DataRank Database

High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease is a research paper published in Movement Disorders Clinical Practice (2025). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 3.08)OA: hybridTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Wojciech Pasławski ORCID,Shervin Khosousi,Ioanna Markaki ORCID,Michael A. Nalls,Andrew B. Singleton

Live enrichment

PubMed:40990085 PMC:PMC13042671 OpenAlex:https://openalex.org/W4414477415

Knut and Alice Wallenberg Foundation

Grant: unidentified

unidentified

Michael J. Fox Foundation for Parkinson's Research

NIH HHS

Knut och Alice Wallenbergs Stiftelse

National Institutes of Health

Region Stockholm

NIH HHS

Region Stockholm

Michael J. Fox Foundation for Parkinson's Research

Knut och Alice Wallenbergs Stiftelse

NIH HHS

FWCI

3.08

Citation Percentile

0.9%

Citation Trend

2026

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.70367

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.70367

publisherhttps://movementdisorders.onlinelibrary.wiley.com/doi/pdf/10.1002/mdc3.70367

publisherhttps://movementdisorders.onlinelibrary.wiley.com/doi/full-xml/10.1002/mdc3.70367

journalhttps://doi.org/10.1002/mdc3.70367

Fields of Study

Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsDementia and Cognitive Impairment Research03 medical and health sciences0302 clinical medicineHumansParkinson DiseaseMaleFemaleAgedCognitive DysfunctionMiddle AgedBiomarkersDopa DecarboxylaseCohort StudiesLongitudinal StudiesMental Status and Dementia TestsNeuropsychological Tests

MeSH Terms

Mental Status and Dementia TestsAgedDopa DecarboxylaseFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsParkinson DiseaseCohort StudiesBiomarkersCognitive Dysfunction

Keywords

Cognitive declineCerebrospinal fluidBiomarkerDiseaseCognitionCognitive impairmentBiomarkersParkinson's DiseaseNonmotor SymptomsDopa Decarboxylase (Ddc)MaleBrief ReportParkinson DiseaseMiddle AgedNeuropsychological TestsMental Status and Dementia TestsCohort StudiesDopa DecarboxylaseHumansFemaleCognitive DysfunctionLongitudinal StudiesAged

High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease

FAIR Checklist

Authors (8)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)